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Abstract
Purpose/Objective—To create and compare consensus clinical target volume (CTV) contours
for computed tomography (CT) and 3 Tesla (3T) magnetic resonance (MR) image-based cervical-
cancer brachytherapy
Materials/Methods—Twenty-three gynecologic radiation oncology experts contoured the same
3 cervical-cancer brachytherapy cases: one Stage IIB near-complete response (CR) case with a
tandem and ovoid, one Stage IIB partial response (PR) case with ovoid with needles and one Stage
IB2 CR case with a ring applicator. CT contours were completed before MRI contours. These
were analyzed for consistency and clarity of target delineation using an expectation maximization
algorithm for simultaneous truth and performance level estimation (STAPLE), with kappa
statistics as a measure of agreement between participants. The conformity index (CI) was
calculated for each of the six data sets. Dice coefficients were generated to compare CT and MR
contours of the same case.
Results—For all 3 cases, the mean tumor volume was smaller on MR than on CT (p<0.001).
Kappa and CI estimates were slightly higher for CT, indicating a higher level of agreement on CT.
DICE coefficients were 89% for the Stage IB2 case with a CR, 74% for the Stage IIB case with a
PR, and 57% for the Stage IIB case with a CR.
Conclusion—When comparing MR- to CT-contoured CTV volumes, the higher level of
agreement on CT may be due to the more distinct contrast visible on the images at the time of
brachytherapy. The largest difference at the time of brachytherapy was in the case with
parametrial extension at diagnosis that had a near-complete response, due to the appearance of the
parametria on CT but not on MR. Based on these results, a 95% consensus volume was generated
for CT and for MR. Online contouring atlases are available for instruction at http://
www.nrgoncology.org/Resources/ContouringAtlases.aspx.
Keywords
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INTRODUCTION
Women with locally advanced cervical cancer require treatment with external beam
radiation (EBRT) combined with brachytherapy (BT) in order to maximize both local and
regional tumor control.1 Survival rates decrease significantly for patients who cannot receive
BT to the primary tumor for various reasons.2,3 BT requires that a tandem be inserted into
the uterus4 to bring the primary cervical tumor to doses in the range of 80–90 Gy, depending
on tumor size, with the dose historically recorded at Point A.5 Proper applicator placement
significantly improves local control and disease-free survival.6 The advantages of 3D–
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imaging at the time of BT include assurance of proper applicator placement, more accurate
definition and treatment of the tumor volume, and delineation of outlines of the OAR for
volume-based dose calculations.
Surveys in the U.S. and Europe demonstrate the increasing use of 3D image-based BT, with
dose given to the at-risk volume rather than to a pre-specified point.7,8 3D image-based BT
results in outstanding local control and a significant reduction in toxicity for cervical-cancer
patients.9–11 Over the past decade, research has evaluated real-time 0.5T MR guidance12 or
post-insertion MR-imaging to assist with tumor delineation and tumor dosimetry. MR-based
planning13 has shown favorable results compared to traditional point A plans.14–16
Contouring guidelines have been published by the GEC-ESTRO to aid the physician in
contouring on 0.2–1.5T MR in a standardized fashion.17,18 A report using 3T MR for both
intracavitary and interstitial gynecologic BT shows the feasibility of using high-strength 3T
MR units for gynecologic BT.19
Contouring accurately on the 3D imaging obtained after applicator placement is critical to
ensure an optimal treatment plan that adequately doses the tumor and minimizes the dose to
the normal-tissue structures. However, no consensus atlas is available in the U.S. to teach
those transitioning from 2D film-based to 3D image-based BT. Prospective clinical trials in
cervical cancer encourage image-based BT, and an atlas will be useful for clinical protocols
and routine practice.
With the increasing availability of CT simulators in Radiation Oncology departments, CT
imaging after BT applicator insertion is easy to implement. MR imaging is feasible but more
difficult for most clinics given the typical location of MR scanners outside of the Radiation
Oncology department. CT/MR-compatible tandem-and-ring and tandem-and-ovoid
applicators are widely available, with or without the addition of interstitial needles. CT-
contouring guidelines were generated in a previous comparison study to MRI; the contours
on CT were consistently wider in the lateral direction.20 A CT scan can define a clinical
tumor volume (CTV) around the lateral borders of the cervix and include any obvious
parametrial extension seen on the scan.20 Uterosacral ligaments may be clearly visualized on
CT when involved with tumor and included in the CTV contours. However, the gross tumor
volume (GTV) may not be adequately delineated on CT due to difficulty in identifying the
tumor consistently even with IV contrast. Furthermore, the superior border of the cervix is
not well visualized on CT, but rather the entire tandem length is activated and the top dwell
is optimized to reduce sigmoid and small bowel dose. In order to create a safety margin
around the visualized volume, both CT20 and MR18 HR-CTV contouring recommendations
stated that the parametrial tissues should be included when involved at diagnosis.
The aim of this study was to compare the contours achieved by a large group of expert
physicians on CT- and MR-based BT cases representing 3 commonly seen scenarios, and to
generate consensus contours for CT and MR brachytherapy atlases to be available on the
Web for online training of physicians.
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Representative physicians from the RTOG Gynecologic Cancer Working Group and other
gynecologic cancer experts received the same 3 cervical-cancer cases as DICOM files which
could be uploaded into their institutions’ contouring software. Physicians responded to a
questionnaire whether they used MR, CT and/or plain film for the majority of their cases.
Each case had a 3T MRI at diagnosis, an MRI and a CT performed at the time of BT (within
an hour of applicator insertion), and clinical drawings based on the exam at diagnosis and at
the time of BT available for physician review. The T2-weighted images were used for
contouring. A CT (120kVP, 200mA, 30-cm field of view, 1.25-mm slice thickness) at the
time of brachytherapy was performed without intravenous contrast for all 3 cases. A
previous contouring study generated a normal-tissue atlas and therefore contouring of the
organs at risk (OAR) was not required.21
Case descriptions
Case 1 was that of a patient with a Stage IIB bulky adenocarcinoma of the cervix. The tumor
involved both the full length of the uterus and the cervix with bilateral parametrial
involvement. At the time of BT, she had a near-complete response to EBRT. Tandem and
ovoid applicator was inserted. In order to treat the full length of the tumor, a tandem was
inserted to the top of the fundus. Due to the presence of tumor, the tandem extended slightly
through the tip of the fundus as was noted on CT, indicating a perforation. In general,
perforations of the uterus most commonly occur in the posterior myometrium and require
immediate repositioning into the uterine canal and antibiotics, followed by treatment. In this
case, the tandem was in the uterine canal and only required slight inferior retraction prior to
planning and treatment, in addition to antibiotics. The doses were optimized to minimize
dose to the adjacent rectum and sigmoid.
Case 2 was that of a patient with a large Stage IIB cervical cancer with a poor response and
difficult anatomy after EBRT. A cavity formed in the region where the cervical tumor had
originally filled the vault and this area was stiff and noncompliant. Given the large amount
of residual tumor remaining after EBRT, a decision was made to insert a tandem and ovoids
with the addition of needles through the ovoids. An air gap was inevitable between the
cervix and the ovoids, even though small ovoids were inserted, given the stiffness of the
tissue and the cavitary formation of the upper vault. Therefore, it was thought that needles
could provide dose where a gap existed with the ovoids.
Case 3 was that of a patient with a Stage IB2 cervical cancer that was bulky at diagnosis
with a complete response to chemoradiation.
CT-based contouring
Instructions mandated that CT contouring be done first without viewing the MRI scan done
at the time of BT. Clinical drawings of the disease at diagnosis, disease extension at the time
of BT and the MRI scan done at diagnosis could be viewed for CT-based contouring. For
CT contouring, physicians drew a CTV-cervix that included the cervix and any notable
parametrial extension at the time of BT, but not the entire parametrial region if not involved,
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similar to the HR-CTV for MRI. The cervix contours started at the level of the applicator.
Modification of the previously published CT-based guidelines did not mandate setting a
parametrial edge other than what was perceived on the scan. On the axial CT, borders were
set as follows:
1. Inferiorly at the level of the ring, contour tissue inside the central ring. For ovoids,
contour tissue to the level of the ovoids. Add vaginal tissue adjacent to the ring if
involved at the time of BT.
2. Superiorly, contour superiorly to the level where the uterus indents (internal os);
draw the next 1 cm as a pointed shape (cone). The approximate dimension (height)
of cervix should be 3 cm.
3. Laterally, parametrial extension should be included in the CT-CTV (and not a
separate structure) if it appears “grey/white” on the CT (i.e., a similar density to the
cervix). There is no need to draw the parametrial region if it does not have
stranding visible on the CT or it is not noted in the clinical drawing. IV Contrast
was not mandated.
MR-based contouring
The MR-defined-CTV (MR-CTV), which was identical to the GEC-ESTRO defined HR-
CTV,18 included the entire cervix as seen on MR plus any parametrial or vaginal extension
(called ‘gray zones’ by the GEC-ESTRO nomenclature on a low-Tesla MR scan)22 seen on
MRI and on clinical examination at the time of BT.17 The Steering Committee determined
that physicians would not be asked to contour the GTV or other structures as the primary
focus was on comparison of CT-CTV to MR-CTV. A comparison of historic versus current
CT and MR contouring guidelines is summarized in Table 1.
Analysis
DICOM files were sent to the Advanced Technology Consortium (ATC) for analysis. The
Computerized Environment for Radiation Research (CERR), an open source MATLAB
(The MathWorks, Natick, MA)-based radiation therapy planning analysis tool23, was used to
analyze the contours and generated the expectation maximization algorithm for
simultaneous truth and performance level estimation (STAPLE) contours24,25. MIM
software (MIM Software, Inc., Cleveland, OH), was used to smooth the edges of any
irregularities. For example, a small portion of the contours extended into the applicator and
were removed from the CTV volume.
The clinical cases were then analyzed for consistency and clarity of target delineation using
STAPLE, with kappa statistics as a measure of agreement between participants. The
conformity index (CI), defined as the ratio between the common (mean) and encompassing
(union) volume of a given pair of contours was calculated for each of the data sets
independently for MR and for CT. STAPLE sensitivity and specificity values were
generated.24,25
Consensus atlases were packaged for review using the FullAccess software package
(Radialogica, St. Louis, MO) and approved by the NRG Oncology Radiotherapy Committee
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prior to posting on the website (www.rtog.org). The software allows viewing of the CT
contour alone or in conjunction with the MR contour.
Comparison of MR versus CT
Dice coefficients were generated to compare CT and MR contours of the same case. The
Dice coefficient is the volume of the intersection divided by the average volume of the two
structures.
Dosimetric comparison
Dosimetric calculations of the D90 and D2cc to the bladder, rectum and sigmoid were
performed using both a standard “point A” plan, to a CT- and to an MR-optimized plan.
Optimization ensured that the CT or MR CTV D90 was maximized while reducing doses to
the organs at risk (OAR), the sigmoid, rectum and bladder as far as was feasible.
RESULTS
A total of 23 physicians contoured as part of this protocol. A total of 50% report using MR
for brachytherapy contouring routinely; 90% use CT for brachytherapy planning either in
addition or instead of MR routinely. The mean, minimum and maximum tumor volumes for
each of the 3 cases on CT and MR are listed in Table 2. The mean tumor volume was
smaller on MR than on CT for all 3 cases (p<0.001). Sensitivity and specificity were similar
between CT and MR (Table 1), indicating very little apparent difference in contours. Kappa
estimates showed substantial agreement among physicians’ contours and were significantly
higher for CT (p=0.048), with a mean value on CT of 0.69 versus 0.66 on MR. Conformity
index was significantly higher for CT compared to MR (p=0.048), indicating a higher level
of agreement on CT. Dice coefficients of the 95% consensus volumes comparing CT to MR
were 57% for case 1, 74% for case 2 and 89% for case 3. A CT atlas and an MR atlas were
generated based on the consensus contours for case 1 (Figure 1), case 2 (Figure 2) and case
3 (Figure 3). The individual physician contours on CT and MR are shown for case 2 (Figure
4) and case 3 (Figure 5). The highest Dice coefficient was found for case 3, which had a
smaller initial tumor with no parametrial involvement, and a small amount of residual
disease to contour, with clear edges of the cervix visible on CT and MR (Figure 3). Case 1, a
patient with a large tumor at diagnosis with parametrial extension that had a good response
to EBRT, had the lowest Dice coefficient due to the appearance of parametrial extension on
the CT but not on the MR (Figure 1). Case 2 had a large tumor at diagnosis and large
residual disease at the time of BT; the contours for this case on both CT and MR (Figure 2)
were large, indicating a good level of concordance between consensus contours in this
clinical scenario.
Dosimetric analysis
Despite a consistently larger volume on CT for all 3 cases, there was no statistically
significant difference in D90 or D2cc OAR comparing CT to MR. Case 1 (large tumor,
intermediate response) had a large difference between CT and MR volumes and also had the
largest difference between MR and CT optimized D90. Table 2 shows the mean DVH values
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for all 3 cases combined However, this did not translate to statistically significant dosimetric
differences (all p>0.05). Table 2 shows the mean DVH values for all 3 cases combined.
DISCUSSION
This study analyzed detailed contouring from a large group of expert gynecologic-cancer
radiation oncologists using 3 different types of brachytherapy applicators to generate CT-
and 3T MR-based cervical-cancer brachytherapy atlases. These atlases can be used in future
cervical-cancer trials and clinical practice. In the three different clinical scenarios analyzed,
the CT-generated CTV contours were more similar among physicians than were the MR-
based contours, indicating a higher degree of reliability. Both CT and MR had high
sensitivity and specificity. There was greater discordance between CT and MR in cases with
parametrial extension and a good response to EBRT than in either cases with no parametrial
extension and a small tumor with a good response to EBRT or cases with parametrial
extension and a poor response to EBRT. The comparison between MR and CT validates
earlier findings showing that the MR-contoured volume was consistently smaller than the
CT-contoured CTV,20 and clarifies that this discrepancy is greatest in patients who have
parametrial extension at diagnosis and a good response to treatment. Case 1, a patient with a
large tumor at diagnosis with parametrial extension that had a good response to EBRT, had
the lowest Dice coefficient due to the appearance of parametrial extension on the CT but not
on the MR. CT may overestimate volume in patients with parametrial extension at diagnosis
that have a good response to EBRT. Conversely, it is possible that with 3T MR, parametrial
regions that were initially involved may no longer enhance due to scar tissue, particularly in
patients that have had a complete clinical response. Whether this lack of enhancement
means that micrometastatic residual disease may still be present is not known. The incidence
of parametrial recurrence in patients who have had a good response on 3T MR but have
residual parametrial extension on CT must be analyzed by large prospective series.
Accurate delineation of the tumor and organs at risk is critical for optimal treatment
planning. Due to the rapid fall-off of dose, imprecise contouring can dramatically change
dosing to the tumor and to the adjacent normal tissue. In this study, the CIs (ratio between
common and encompassing volumes) of a large number of gynecologic experts were
between 0.37–0.48. For each clinical scenario, the CI was slightly higher for CT than for
MR, likely due to the distinction on CT between involved ‘grey’ region and non-
involvement of the parametria. All 3 cases had 3T MRI, which provides excellent soft-tissue
resolution.
In a study analyzing the agreement between target volumes, as delineated by two observers
on two different MR image planes, the inter-observer and inter-planar CIs were ranged from
0.7–0.8,26 with small volumetric and dosimetric variations.27 The CIs in our analysis were
lower due to the complexity of the cases and the large number of expert physicians
contouring, though all had significant experience contouring on both MR and CT-based
implants.
In a report of 6 cases contoured by 10 physicians, results showed that, due to lower
delineation uncertainties when compared to GTV and IR-CTV, the HR-CTV may be
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considered the most robust volume for dose prescription and optimization.28 In that study,
no comparison to CT was made. The dosimetric consequence on MR CTV was a single
fraction mean relative standard deviation of 8–10% and a cumulative whole-treatment
uncertainty of +/−5 Gy.29 Similarly, in this study, we chose to only focus on the MR-CTV
on MR and the CT-CTV on CT.
The DICE coefficient of the 95% consensus volumes comparing CT to MR was highest
(89%) for the case with no parametrial extension and a good response to EBRT, the scenario
most often taught in contouring workshops. These cases are therefore the least likely to
benefit from the use of MR. In contrast, the scenario with a large tumor volume at diagnosis
that had a near complete response had the lowest DICE coefficient (57%), with significant
differences between CT and MR contours in the region of the parametria (Figure 1). In this
scenario, caution must be exerted when using MR to contour the CTV in that even amongst
expert physicians, the parametria may appear to have a complete response, whereas on CT,
this region appears as scar and is treated to full dose as part of the CTV. Whether MR may
have a higher rate of parametrial failure as a consequence of this potential undercontouring,
or whether CT may overdose the parametria and/or organs at risk in this scenario is
unknown. In order to safely treat all patients presenting with this scenario, caution in
covering the full parametria is recommended at this time. The limitations of intracavitary
techniques in the setting of bulky parametrial involvement, however, must be realized, and
when appropriate, interstitial techniques may need to be considered.
In the scenario with a large tumor that had an incomplete response, an applicator that
incorporates interstitial needles into the ovoids was utilized. This scenario resulted in a
DICE coefficient of 74% comparing CT to MR consensus volumes. The highest discrepancy
was again in the parametrial region, but more parametrial tissue was contoured on the MR
compared to case 1, resulting in the higher DICE coefficient. This reiterates the importance
of careful evaluation of the parametria on MR. For centers where only a CT is available, the
CT suffices to cover adequate parametrial extension in all scenarios if the contours extend to
the most lateral aspect of the parametrial tissue.
Based on these three scenarios, parametrial extension may help clarify when patients may
benefit from an MRI at the time of brachytherapy. In cases with no parametrial extension,
MR and CT have nearly identical CTV contours. For cases with parametrial extension and a
poor response to treatment, MR and CT have similar CTV contours. Cases with parametrial
extension with a complete response benefit the most from utilizing both MRI and CT. Table
2 summarizes the current recommendations for CT –based contouring.
A direct comparison of CT to 0.2T MR planning after insertion in the same patient showed
that the CT-contoured images were wider in the region of the parametria.20 The first
prospective study using mainly CT-based planning in comparison to plain X-ray-based
planning, the French STIC trial, showed significant improvements with CT in the subgroup
receiving chemo-radiation for locally advanced disease in toxicity reduction (22% to 2.6%),
and not significant improvements in local control (74% to 79%), disease-specific survival
(55% to 60%) and overall survival (65% to 74%).9 Other institutional series using CT30,31
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confirm that very high rates of local control (90% and above) are achievable with limited
rates of grade 3 or higher morbidity.
Conclusion
To date, no other study has compared consensus contours generated by a large group of
expert gynecologic radiation oncologists using CT and 3T MR. MRI-contoured volumes are
smaller than CT volumes, particularly in cases with parametrial extension, and depend on
the amount of tumor regression. CT has a higher level of agreement that may be due to the
more distinct contrast between tissues on the images at the time of brachytherapy. A 95%
consensus volume was generated for CT and for MR online contouring atlases available for
instruction at http://www.nrgoncology.org/Resources/ContouringAtlases.aspx based on
these results.
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To date, no other study has compared consensus contours generated by a large group of
expert gynecologic radiation oncologists using CT and 3T MR. MRI-contoured volumes
are smaller than CT volumes, particularly in cases with parametrial extension, and
depend on the amount of tumor regression. CT has a higher level of agreement that may
be due to the more distinct contrast between tissues on the images at the time of
brachytherapy. A 95% consensus volume was generated for CT and for MR online
contouring atlases available for instruction at http://www.nrgoncology.org/Resources/
ContouringAtlases.aspx. based on these results.
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Axial, sagittal and coronal images of CT and MRI for case 1 showing a tandem and ovoid
applicator with consensus contours for MR (light blue) and for CT (red)
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Axial, sagittal and coronal images of CT and MRI for case 2 showing a tandem and ovoid
with needles applicator with consensus contours for MR (light blue) and for CT (red)
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Axial, sagittal and coronal images of CT and MRI for case 3 showing a tandem and ring
applicator with consensus contours for MR (light blue) and for CT (red)
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Table 1
Comparison of contouring guidelines in locally advanced cervical cancer
Clinical Target Volume Contouring Guidelines for MR and CT
MR (2005)32 Contour the whole cervix and the presumed
extracervical tumor extension at time of BT. Tumor
extension is defined by clinical examination
(visualisation and palpation) and by MRI findings at
time of brachytherapy (BT) taking into account
tumor spread at diagnosis as indicated on clinical
examination and initial MRI for staging.
Pathologic residual tissue(s) as defined by palpable
indurations and/or residual grey zones in
parametria, uterine corpus, vagina or rectum and
bladder on MR are included in HR CTV. No safety
margins are added.
CT (2007)20 Contour entire cervix as seen on CT
1. Inferiorly, start contour at superior level of applicator.
2. Superiorly, contour to level at which uterine vessels first abut cervical tissue (if intravenous (IV) contrast administered)
to point at which volume expands (indicating presence of uterine tissue), or to point at which uterine cavity appears.
a. Add two slices of contour (with decreasing diameters) around tandem superiorly to cover conical cervical apex.
b. Measure height of cervix to ensure adequate coverage (average height approximately 3 cm). Divide parametria into
inner half and outer half. Contour parametria entire height of the cervix.
CT (2014, this
manuscript)
1. Inferiorly at the level of the ring, contour tissue inside the central ring. For ovoids, contour tissue to the level of the
ovoids. Add vaginal tissue adjacent to the ring if involved at the time of BT.
2. Superiorly, contour superiorly to the level where the uterus indents (internal os); draw the next 1 cm as a pointed shape
(cone). The approximate dimension (height) of cervix should be 3 cm.
4. Laterally, parametrial extension should be included in the CT-CTV (and not a separate structure) if it appears “grey/
white” on the CT (i.e., a similar density to the cervix). There is no need to draw the parametrial region if it does not have
stranding visible on the CT or it is not noted in the clinical drawing. IV Contrast is not mandated.
5. Take into account tumor present on clinical examination and MRI findings at time of BT if available. Disease extension
on clinical exam and MRI at the time of diagnosis should be contoured in a low dose region (Intermediate Risk (IR)-
CTV).
6. Pathologic residual tissue(s) identified in the uterus, vagina or rectum and bladder are included in the CT-CTV.
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